Strategic Initiative

Slingshot members are tracking this corporate initiative:

Leap Therapeutics (LPTX) and BeiGene (BGNE) Announce Exclusive Option and License Agreement for DKN-01 + $27 Million Equity Financing

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BGNE

100%
LPTX

100%

Additional Information

Clinical Data - BeiGene granted option to develop and commercialize Leap's DKN-01 in the Asia Pacific Region, excluding Japan
- Initiation of combination studies of Leap's DKN-01 with BeiGene's anti-PD-1 antibody tislelizumab planned
 In addition, Leap announced entering into an agreement for a $27 million equity financing with BeiGene and two institutional investors.
https://investors.le...
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jan 03, 2020
Projected Implementation:
Q1, 2020
Relevance Tracked Until:
Q2, 2020
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Dkn-01